JOHNSON & JOHNSON — 13F Holdings & Portfolio
CIK 200406 · latest 13F-HR filed 2026-08-06
JOHNSON & JOHNSON manages $798.7M in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PTGX (37.59%), NBTX (26.55%), MGTX (11.23%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 2, added to 9, and trimmed 4.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
NEW BRUNSWICK, NJ 08933
$798.7M
Long-equity book
15
Distinct positions
2026-06-30
Filed 2026-08-06
+1 / −2 / ↑9 / ↓4
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- PROTAGONIST THERAPEUTICS INC$42.1M +16.3%
- NANOBIOTIX$38.4M +22.1%
- MEIRAGTX HLDGS PLC$32.2M +56.0%
- RAPPORT THERAPEUTICS INC$18.5M +33.2%
- LEGEND BIOTECH CORP$8.8M +59.6%
Top Trims
- CVRX INC-$17.4M -45.7%
- PROCEPT BIOROBOTICS CORP-$869.8K -9.7%
- NEUMORA THERAPEUTICS INC.-$462.4K -12.8%
- STANDARD BIOTOOLS INC-$30.1K -10.5%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $300.2M | 37.59% | 2,449,183 | SH |
| 2 | NANOBIOTIX | NBTX | 63009J107 | $212.0M | 26.55% | 5,623,816 | SH |
| 3 | MEIRAGTX HLDGS PLC | MGTX | G59665102 | $89.7M | 11.23% | 6,641,064 | SH |
| 4 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $74.4M | 9.31% | 1,784,517 | SH |
| 5 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $32.4M | 4.06% | 1,979,173 | SH |
| 6 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $23.5M | 2.95% | 814,586 | SH |
| 7 | CVRX INC | CVRX | 126638105 | $20.7M | 2.59% | 4,024,861 | SH |
| 8 | XENCOR INC | XNCR | 98401F105 | $12.0M | 1.51% | 748,062 | SH |
| 9 | CEREBRAS SYSTEMS INC | CBRS | 15675D103 | $11.8M | 1.48% | 53,586 | SH |
| 10 | FATE THERAPEUTICS INC | FATE | 31189P102 | $9.1M | 1.14% | 3,379,064 | SH |
| 11 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $8.1M | 1.01% | 357,939 | SH |
| 12 | NEUMORA THERAPEUTICS INC. | NMRA | 640979100 | $3.1M | 0.39% | 1,849,445 | SH |
| 13 | VOR BIOPHARMA INC | VOR | 929033207 | $989.2K | 0.12% | 53,732 | SH |
| 14 | STANDARD BIOTOOLS INC | LAB | 34385P108 | $256.7K | 0.03% | 311,967 | SH |
| 15 | ADICET BIO INC | ACET | 007002207 | $196.8K | 0.02% | 22,779 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-06 | $798.7M | 15 | 0000904454-26-000435 |
| 2026-03-31 | 2026-05-13 | $652.4M | 16 | 0000904454-26-000280 |
| 2025-12-31 | 2026-03-18 | $555.0M | 17 | 0000904454-26-000192 |
| 2025-09-30 | 2026-03-18 | $503.9M | 20 | 0000904454-26-000190 |